» Articles » PMID: 35695911

Drug Repurposing-an Emerging Strategy in Cancer Therapeutics

Overview
Specialty Pharmacology
Date 2022 Jun 13
PMID 35695911
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug's original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.

Citing Articles

Rifampicin Repurposing Reveals Anti-Melanogenic Activity in B16F10 Melanoma Cells.

Lee Y, Hyun C Molecules. 2025; 30(4).

PMID: 40005210 PMC: 11858211. DOI: 10.3390/molecules30040900.


Drug Repurposing and Nanotechnology for Topical Skin Cancer Treatment: Redirecting toward Targeted and Synergistic Antitumor Effects.

Martins M, Veiga F, Paiva-Santos A, Pires P ACS Pharmacol Transl Sci. 2025; 8(2):308-338.

PMID: 39974652 PMC: 11833728. DOI: 10.1021/acsptsci.4c00679.


Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer.

Piastra V, Ganci F, Sacconi A, Pranteda A, Allegretti M, Bernardini R J Exp Clin Cancer Res. 2024; 43(1):234.

PMID: 39164711 PMC: 11334304. DOI: 10.1186/s13046-024-03150-4.


In Silico Drug Repurposing Against PSMB8 as a Potential Target for Acute Myeloid Leukemia Treatment.

Tukel E, Ates O, Kiraz Y Mol Biotechnol. 2024; .

PMID: 38954355 DOI: 10.1007/s12033-024-01224-4.


The global patent landscape of emerging infectious disease monkeypox.

Cai Y, Zhang X, Zhang K, Liang J, Wang P, Cong J BMC Infect Dis. 2024; 24(1):403.

PMID: 38622539 PMC: 11017537. DOI: 10.1186/s12879-024-09252-w.


References
1.
Abou-Issa H, Alshafie G . Celecoxib: a novel treatment for lung cancer. Expert Rev Anticancer Ther. 2004; 4(5):725-34. DOI: 10.1586/14737140.4.5.725. View

2.
Adamo P, Ladomery M . The oncogene ERG: a key factor in prostate cancer. Oncogene. 2015; 35(4):403-14. DOI: 10.1038/onc.2015.109. View

3.
Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M . Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010; 11(5):421-8. PMC: 3792651. DOI: 10.1016/S1470-2045(10)70054-1. View

4.
Aftab B, Dobromilskaya I, Liu J, Rudin C . Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res. 2011; 71(21):6764-72. PMC: 3206167. DOI: 10.1158/0008-5472.CAN-11-0691. View

5.
Ali R, Toh H, Chia W . The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. Trials. 2011; 12:261. PMC: 3271983. DOI: 10.1186/1745-6215-12-261. View